U.S. flag An official website of the United States government
  1. Home
  2. About FDA
  3. Reports, Manuals, & Forms
  4. Reports
  5. Economic Impact Analyses of FDA Regulations
  6. Crabmeat; Amendment of Common or Usual Name Regulation (Final Rule)
  1. Reports

Crabmeat; Amendment of Common or Usual Name Regulation (Final Rule)

Crabmeat; Amendment of Common or Usual Name Regulation (Final Rule)

In a final rule published on July 3, 1995, the Food and Drug Administration (FDA) amended the common or usual name regulation for crabmeat by adding “Brown King crabmeat” as the sole common or usual name for the species Lithodes aequispina. In response to the 2017 Consolidated Appropriations Act, FDA is amending the common or usual name regulation for the species Lithodes aequispina from “Brown King crabmeat” to “Golden King crabmeat.” The estimated present value of the costs of this final rule range from $1.5 million to $7.5 million, with a mean estimate of $3.4 million (2016$), while the estimated present value of the benefits of this final rule are zero. The estimated present value of the net benefits of this final rule range from -$7.5 million to -$1.5 million, with a mean estimate of -$3.4 million (2016$). The estimated annualized costs of this final rule range from $0.1 million to $0.5 million, with a mean estimate of $0.2 million, using a 3 percent discount rate, and from $0.1 million to $0.7 million, with a mean estimate of $0.3 million, using a 7 percent discount rate (2016$). Estimated annualized benefits of this final rule are zero. The estimated annualized net benefits of this final rule range from -$0.5 million to -$0.1 million, with a mean estimate of -$0.2 million, using a 3 percent discount rate, and from -$0.7 million to -$0.1 million, with a mean estimate of -$0.3 million, using a 7 percent discount rate (2016$). Finally, there are no cost savings associated with this final rule.

Regulatory Impact Analysis

Crabmeat; Amendment of Common or Usual Name Regulation (Final Rule) RIA (PDF-122KB)

Federal Register: Vol. 83, No. 86, Thursday, May 3, 2018, pp. 19,429 – 19,431

Docket: FDA-2018-N-1438